1. Home
  2. FOLD vs FUL Comparison

FOLD vs FUL Comparison

Compare FOLD & FUL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FOLD
  • FUL
  • Stock Information
  • Founded
  • FOLD 2002
  • FUL 1887
  • Country
  • FOLD United States
  • FUL United States
  • Employees
  • FOLD N/A
  • FUL N/A
  • Industry
  • FOLD Biotechnology: Pharmaceutical Preparations
  • FUL Home Furnishings
  • Sector
  • FOLD Health Care
  • FUL Industrials
  • Exchange
  • FOLD Nasdaq
  • FUL Nasdaq
  • Market Cap
  • FOLD 2.9B
  • FUL 3.2B
  • IPO Year
  • FOLD 2007
  • FUL N/A
  • Fundamental
  • Price
  • FOLD $7.58
  • FUL $60.79
  • Analyst Decision
  • FOLD Strong Buy
  • FUL Hold
  • Analyst Count
  • FOLD 10
  • FUL 5
  • Target Price
  • FOLD $26.89
  • FUL $67.25
  • AVG Volume (30 Days)
  • FOLD 3.8M
  • FUL 308.2K
  • Earning Date
  • FOLD 07-31-2025
  • FUL 09-24-2025
  • Dividend Yield
  • FOLD N/A
  • FUL 1.54%
  • EPS Growth
  • FOLD N/A
  • FUL N/A
  • EPS
  • FOLD N/A
  • FUL 1.84
  • Revenue
  • FOLD $571,160,000.00
  • FUL $3,527,969,000.00
  • Revenue This Year
  • FOLD $20.98
  • FUL N/A
  • Revenue Next Year
  • FOLD $20.74
  • FUL $3.24
  • P/E Ratio
  • FOLD N/A
  • FUL $33.20
  • Revenue Growth
  • FOLD 25.35
  • FUL N/A
  • 52 Week Low
  • FOLD $5.51
  • FUL $47.56
  • 52 Week High
  • FOLD $12.65
  • FUL $85.89
  • Technical
  • Relative Strength Index (RSI)
  • FOLD 69.88
  • FUL 58.19
  • Support Level
  • FOLD $7.40
  • FUL $60.56
  • Resistance Level
  • FOLD $7.80
  • FUL $62.64
  • Average True Range (ATR)
  • FOLD 0.22
  • FUL 1.29
  • MACD
  • FOLD 0.01
  • FUL 0.32
  • Stochastic Oscillator
  • FOLD 87.61
  • FUL 79.94

About FOLD Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.

About FUL H. B. Fuller Company

H.B. Fuller Co manufactures and sells adhesives, sealants, and other chemical-based products. The company organizes itself into three segments: Hygiene, Health and Consumable Adhesives, Engineering Adhesives and Construction Adhesives. It generates the maximum revenue from hygiene, health and consumable adhesives. This segment produces and supplies a full range of specialty industrial adhesives such as thermoplastic, thermoset, reactive, water-based and solvent-based products for applications in various markets, including packaging , converting, nonwoven and hygiene (disposable diapers, feminine care and medical garments) and health and beauty. The company generates around half of its revenue in the United States.

Share on Social Networks: